查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016232

可吸收血管支架市场：依适应症、材料、支架直径、支架长度及最终用户划分－2026-2032年全球市场预测

Resorbable Vascular Scaffold Market by Indication, Material, Scaffold Diameter, Scaffold Length, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，可吸收血管支架市场价值将达到 4.6465 亿美元，到 2026 年将成长至 5.0068 亿美元，到 2032 年将达到 7.7998 亿美元，复合年增长率为 7.68%。

主要市场统计数据
基准年 2025 4.6465亿美元
预计年份：2026年 5.068亿美元
预测年份：2032年 7.7998亿美元
复合年增长率 (%) 7.68%

对可吸收血管支架的临床机会、工程原理、监管环境和相关人员趋势进行权威说明。

可吸收血管支架是材料科学与介入性心臟病学融合的产物，旨在恢復血管通畅性，同时避免长期植入永久性金属植入。其设计理念是在血管治疗期间提供临时机械支撑和可控药物释放型，随后逐渐被吸收，可能会减少与永久性植入相关的延迟性不利事件。本导论分析系统地说明了推动临床应用进展的技术进步、临床驱动因素以及相关人员生态系统。

重建可吸收血管支架的前景：定义材料科学、手术实务和临床证据的颠覆性转折点。

可吸收血管支架的前景已从概念性的可能性转变为实际的工程和临床改进。镁合金和聚乳酸衍生物等生物可吸收材料的进步提高了径向强度、可控的降解速率和生物相容性。同时，装置结构的迭代改进（例如减薄支架梁、优化支架形态、开发新一代药物涂层等）缓解了最初对支架血栓症和血管回缩的担忧。血管内成像技术和操作流程的改进降低了植入的变异性，而药物释放型支架的跨学科经验正被应用于优化抗血小板策略和最佳植入实践。

评估 2025 年美国对可吸收血管支架国际供应链征收关税对营运、采购和创新的综合影响。

对医疗设备零件和成品征收关税可能会对可吸收血管支架的研发和商业化产生多方面的影响。关税带来的成本压力将使依赖国际供应链获取关键投入（例如特种合金、聚合物原材料和精密製造设备）的製造商的采购变得更加复杂。因此，核准的价格上涨和利润率下降可能会减缓对临床试验、生产规模扩大和全球市场准入计画的投资。随着医疗设备定价趋势的变化，医院采购部门可能会重新评估其采购决策，而报销谈判也可能越来越关注治疗总成本和生命週期经济效益，而不仅仅是单价。

深入分析了与临床适应症、支架材料、设备尺寸和最终用户环境相关的细分，这些因素影响着治疗管道和应用。

从细分观点来看，适应症、材料、最终用户状况、支架直径和支架长度如何影响临床选择、装置设计优先顺序和商业性定位就显而易见了。就适应症而言，临床环境分为冠状动脉疾病和周边动脉疾病，其中冠状动脉疾病又细分为急性冠状动脉症候群和稳定性心绞痛。周边动脉疾病则进一步分为间歇性跛行和严重下肢缺血。每种临床途径都需要不同的机械性质和药物释放型策略。在急性冠状动脉介入治疗中，快速释放和可控吸收通常是优先考虑的因素，以利于早期治疗；而周边肢体缺血介入治疗则需要长期径向强度和更高的抗压强度。

区域展望整合了美洲、欧洲、中东、非洲和亚太地区的临床基础设施、法规结构、报销趋势和部署模式。

美洲、欧洲、中东、非洲和亚太地区的临床基础设施、法规结构、报销管道和医疗专业人员偏好等因素，导致区域绩效和应用趋势有显着差异。在美洲，集中的介入治疗专业中心和高频次的冠状动脉介入治疗课程有助于快速掌握技能并儘早应用。该地区的监管流程和与支付方的谈判强调可靠的临床终点和长期安全性，促使製造商除了提供随机对照试验数据外，还需提供成熟的上市后数据。

针对支架製造商之间的合作关係、临床研发管线、生产规模、智慧财产权定位和竞争优势等方面的策略竞争情报。

可吸收血管支架研发企业的竞争格局受临床证据的累积、生产规模、智慧财产权差异化和商业性伙伴关係等因素的影响。主要企业凭藉强大的临床研发管线脱颖而出，这些管线能够证明产品在多种冠状动脉和周边血管适应症中的安全性；而其他企业则专注于提升生产能力，以确保产品性能稳定并符合监管要求。与影像设备製造商、契约製造製造商和临床研究机构建立合作关係可以加速证据的累积并促进市场准入。同时，企业内部的精密挤出和灭菌能力有助于品质和成本控制。

为製造商、临床医生和投资者提供实用建议，以加速临床应用并降低商业性和程序风险。

产业领导企业可以采取切实措施，在应对临床和商业性不确定性的同时，加速产品应用。首先，将临床开发项目与不同的适应症管道相匹配。优先考虑那些瞬时支架能够带来明确治疗益处的高影响力适应症，并设计包含影像学和患者报告结果的测试，以增强产品的价值主张。其次，透过原料来源多元化和评估区域製造地，投资于价值链的韧性，以减轻贸易政策波动的影响，并确保向高使用率设施提供可预测的设备供应。

采用混合方法研究途径，结合专家访谈、临床文献综述、註册分析和供应链检验。

本分析的调查方法融合了定性和定量方法，以确保获得可靠且可操作的见解。主要调查包括对介入性心臟病专家、週边血管专家、采购经理和监管专家进行结构化访谈，以了解他们对器械性能、手术流程和采购重点的实际观点。次要调查包括对同行评审的临床文献、器械註册资讯、监管申报文件和专利资讯披露进行系统性回顾，以全面检验临床结果、安全讯号和技术趋势。

总结了影响可吸收支架未来发展和商业性成功的策略挑战、持续存在的障碍以及关键成功因素。

总之，可吸收血管支架在临床应用潜力和工程创新方面展现出令人瞩目的优势，但其成功应用于常规临床实践取决于材料科学、实证医学证据、监管策略和商业性实施等方面的协调进展。目前仍存在许多障碍，包括需要长期安全性数据、供应链韧性以应对贸易政策波动，以及与支付方建立清晰的沟通管道，这些支付方不仅考虑单位成本，还关注整个生命週期的效益。然而，如果这些障碍得以克服，支架技术有望在特定冠状动脉和周边血管疾病的治疗中带来变革性转变。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 可吸收血管支架市场：依适应症划分

  • 冠状动脉疾病
    • 急性冠状动脉症候群
    • 稳定性心绞痛
  • 周边动脉疾病
    • 间歇性跛行
    • 严重下肢缺血

第九章：可吸收血管支架市场：依材料分类

  • 镁
  • 聚乳酸

第十章 可吸收血管支架市场：依支架直径划分

  • 3毫米或更小
  • 3毫米或以上

第十一章 可吸收血管支架市场：依支架长度划分

  • 18～28mm
  • 超过 28 毫米
  • 18毫米或更小

第十二章 可吸收血管支架市场：依最终用户划分

  • 门诊手术中心
  • 心臟中心
  • 医院

第十三章 可吸收血管支架市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 可吸收血管支架市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 可吸收血管支架市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国可吸收血管支架市场

第十七章：中国可吸收血管支架市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • BIoTronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • Meril Life Sciences Private Limited
  • MicroPort Scientific Corporation
  • Shandong Huaan BIoTechnology Co., Ltd.
  • Terumo Corporation
  • Xeltis AG
  • Zorion Medical
Product Code: MRR-035AB9C0DAAB

The Resorbable Vascular Scaffold Market was valued at USD 464.65 million in 2025 and is projected to grow to USD 500.68 million in 2026, with a CAGR of 7.68%, reaching USD 779.98 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 464.65 million
Estimated Year [2026] USD 500.68 million
Forecast Year [2032] USD 779.98 million
CAGR (%) 7.68%

An authoritative introduction to clinical opportunity, engineering principles, regulatory landscape, stakeholder dynamics around resorbable vascular scaffolds

Resorbable vascular scaffolds represent a convergence of materials science and interventional cardiology intended to restore vessel patency while eliminating the long-term presence of a permanent metallic implant. The design rationale is to provide transient mechanical support and controlled drug elution during the period of vessel healing before gradual resorption, thereby potentially reducing late adverse events linked to permanent implants. This introductory analysis contextualizes technological evolution, clinical drivers, and the stakeholder ecosystem that together determine the pace of clinical integration.

Clinicians, device engineers, regulatory authorities, and hospital procurement teams each play a distinct role in value creation and risk mitigation. Clinicians demand robust safety and efficacy evidence across acute and chronic coronary presentations as well as peripheral arterial conditions. Engineers pursue thinner strut geometry, predictable degradation profiles, and optimized drug-polymer matrices to improve deliverability and reduce restenosis. Regulators emphasize long-term follow-up and imaging endpoints, while purchasers weigh procedural cost, inventory complexity, and reimbursement alignment. Taken together, these forces set the agenda for product development, clinical trial design, and go-to-market strategies that will define which scaffold concepts progress to routine clinical use.

Defining disruptive inflection points in materials science, procedural practice, and clinical evidence reshaping the resorbable vascular scaffold landscape

The landscape for resorbable vascular scaffolds has shifted from conceptual promise to pragmatic engineering and clinical refinement. Advances in bioresorbable materials such as magnesium alloys and polylactic acid derivatives have improved radial strength, controlled degradation kinetics, and biocompatibility. Simultaneously, iterative improvements in device architecture-thinner struts, enhanced scaffold geometries, and next-generation drug coatings-have mitigated early concerns around scaffold thrombosis and vessel recoil. Improved intravascular imaging and procedural techniques have reduced deployment variability, and cross-disciplinary learning from drug-eluting stents has informed optimal antiplatelet strategies and implantation best practices.

Beyond materials and technique, the evidence base has matured; post-market registries and focused randomized studies continue to refine the clinical niches where resorbable scaffolds provide incremental benefit. Regulatory approaches have evolved to balance accelerated access with demands for robust longitudinal safety data, prompting manufacturers to embed extended follow-up and imaging endpoints into development pathways. Economically, hospitals and payers increasingly demand clear value narratives tied to reduced long-term complications and simplified lifelong imaging or intervention. Together, these transformative shifts are realigning R&D priorities, shaping reimbursement conversations, and compressing the time from prototype to clinical adoption for technologies that can demonstrably improve patient outcomes.

Assessing compounded operational, procurement, and innovation consequences of 2025 US tariffs on international supply chains for resorbable vascular scaffolds

The introduction of tariffs affecting medical-device components and finished goods can exert a multi-dimensional impact on resorbable vascular scaffold development and commercialization. Tariff-driven cost pressures raise procurement complexity for manufacturers that rely on international supply chains for key inputs such as specialized alloys, polymer feedstocks, and precision manufacturing equipment. In turn, consented price increases or margin compression can slow investment in clinical trials, manufacturing scale-up, and global market entry plans. Hospital procurement teams may recalibrate purchasing decisions as device pricing dynamics shift, while reimbursement negotiations will increasingly factor in total cost of care and lifecycle economics rather than unit price alone.

Strategic responses to tariff-induced disruption include near-shoring of component manufacturing, renegotiation of supplier contracts, and redesign for material sourcing flexibility. These measures require lead time and capital allocation but can increase resilience against future policy volatility. In addition, device developers may accelerate development of cost-effective production processes or prioritize markets with favorable trade terms to preserve commercial momentum. Clinical adoption pathways may experience temporal variation as providers weigh the clinical advantages of resorbable solutions against short-term budgetary constraints, creating differentiated windows of opportunity across geographies and care settings.

Segmentation-focused insights into clinical indications, scaffold materials, device dimensions, and end-user settings that shape therapeutic pathways and adoption

A segmentation lens reveals how indication, material, end-user context, scaffold diameter, and scaffold length each inform clinical selection, device design priorities, and commercial positioning. Based on indication the clinical environment spans Coronary Artery Disease and Peripheral Arterial Disease, with Coronary presentations further divided into Acute Coronary Syndrome and Stable Angina, and Peripheral presentations distinguished between Claudication and Critical Limb Ischemia. These clinical pathways demand distinct mechanical profiles and drug-elution strategies: acute coronary interventions often prioritize rapid deliverability and controlled resorption to support early healing, while peripheral limb ischemia interventions require longer-term radial strength and enhanced durability against compressive forces.

Material segmentation across Magnesium and Polylactic Acid offers different trade-offs between strength, degradation timeline, and biocompatibility, which manifest in device handling and imaging profiles. End-user segmentation encompassing Ambulatory Surgical Centers, Cardiac Centers, and Hospitals drives differences in procedural volume, infrastructure, and purchasing cycles, thereby influencing inventory strategy and sales engagement models. Scaffold diameter segmentation distinguishing Less Than 3 Millimeter and Three Millimeter And Above categories directly affects device geometry and clinical indications, while scaffold length segmentation across Eighteen To Twenty Eight Millimeter, Greater Than Twenty Eight Millimeter, and Less Than Eighteen Millimeter brackets impacts delivery systems, overlapping strategies, and inventory breadth. Consequently, manufacturers must align material choice and dimensional platforms to specific clinical indications and end-user workflows to optimize adoption and economic viability.

Regional perspectives integrating clinical infrastructure, regulatory frameworks, reimbursement dynamics, and adoption patterns across Americas, EMEA and Asia-Pacific

Regional performance and adoption dynamics differ markedly and are shaped by clinical infrastructure, regulatory frameworks, reimbursement pathways, and practitioner preferences across Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit concentrated centers of interventional expertise and high-volume coronary programs that facilitate rapid procedural learning and early adopter behavior. Regulatory pathways and payer negotiations in this region emphasize robust clinical endpoints and long-term safety, which incentivizes manufacturers to present mature post-market evidence alongside randomized data.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement models create a mosaic of access; several jurisdictions prioritize health-technology assessment criteria and long-term cost-effectiveness, prompting tailored market access strategies. Asia-Pacific includes markets with variable clinical capacity but high procedural growth, where scalable manufacturing and local regulatory engagement can accelerate penetration when coupled with clinician training programs. Across all regions, infrastructure for intravascular imaging, operator training ecosystems, and local reimbursement nuances determine the pace at which resorbable scaffolds shift from specialized centers to broader clinical practice. Consequently, a differentiated geographic strategy that aligns evidence generation and commercialization investments with regional clinical and payer priorities is essential for sustained uptake.

Strategic corporate intelligence on partnerships, clinical pipelines, manufacturing scale, IP positioning, and competitive differentiation among scaffold makers

Competitive dynamics among companies developing resorbable vascular scaffolds are shaped by clinical evidence generation, manufacturing scale, intellectual property differentiation, and commercial partnerships. Leading developers differentiate through robust clinical pipelines that demonstrate safety across diverse coronary and peripheral indications, while others emphasize manufacturing competence to ensure consistent device performance and regulatory compliance. Partnerships with imaging companies, contract manufacturers, and clinical research organizations can accelerate evidence generation and streamline market entry, whereas in-house capabilities in precision extrusion and sterilization provide control over quality and cost.

Corporate strategies increasingly include co-development agreements with hospital systems and specialist investigator networks to secure real-world data commitments and adoption pathways. Licensing arrangements and selective mergers or acquisitions can expand material science capabilities or geographic reach, but they also require careful integration planning to preserve clinical momentum. Intellectual property positioning around polymer formulations, alloy processing, and scaffold architecture remains a strategic asset and a lever in negotiations with potential partners. For companies and investors, success will hinge on the ability to synchronize clinical proof points with scalable manufacturing and targeted commercial rollouts that reflect differences in end-user requirements and regional access conditions.

Actionable recommendations for manufacturers, clinicians, and investors to accelerate clinical adoption and reduce commercial and procedural risk

Industry leaders can take concrete actions to accelerate adoption while managing clinical and commercial uncertainty. First, align clinical development programs with differentiated indication pathways; prioritize high-impact presentations where transient scaffolding offers clear therapeutic advantages and design trials that incorporate imaging and patient-reported outcomes to strengthen value narratives. Second, invest in supply chain resilience by diversifying raw material sources and evaluating localized manufacturing hubs to reduce exposure to trade policy shocks and to ensure predictable device supply to high-volume centers.

Third, engage proactively with payers and health-technology assessment bodies to establish reimbursement paradigms that reflect total cost of care and long-term benefits. Fourth, build clinician education programs that combine hands-on training with imaging-guided implantation protocols to reduce procedural variability and improve outcomes. Fifth, pursue strategic partnerships that combine materials expertise, manufacturing scale, and clinical trial infrastructure to shorten time-to-market while maintaining quality. Finally, adopt a phased commercialization strategy that sequences initial market entry into centers of excellence before broader roll-out, thereby accumulating real-world evidence and refining pricing and service models in response to early performance data.

Mixed-methods research approach integrating primary expert interviews, clinical literature review, registry analysis, and supply chain validation

The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure robust and actionable findings. Primary research comprised structured interviews with interventional cardiologists, peripheral vascular specialists, procurement leaders, and regulatory experts to capture frontline perspectives on device performance, procedural workflows, and purchasing priorities. Secondary research included systematic review of peer-reviewed clinical literature, device registries, regulatory filings, and patent disclosures to triangulate clinical outcomes, safety signals, and technological innovation trends.

Supply chain mapping identified critical input dependencies and manufacturing bottlenecks, while commercial channel analysis examined hospital procurement processes and end-user adoption levers. Findings were validated through expert advisory panels and cross-checked with longitudinal device performance reports where available. Throughout the process, emphasis was placed on transparent documentation of data sources, methodological limitations, and assumptions to ensure that conclusions are reproducible and suitable for operational planning. This mixed-methods approach yields insights that are both clinically relevant and commercially executable.

Concluding synthesis of strategic imperatives, persistent barriers, and critical success factors shaping trajectory and commercial success of resorbable scaffolds

In conclusion, resorbable vascular scaffolds occupy a compelling nexus of clinical promise and engineering innovation, but their successful translation into routine practice depends on coordinated progress across materials science, evidence generation, regulatory strategy, and commercial execution. Persistent barriers include the need for long-term safety data, supply chain resilience in the face of trade policy fluctuations, and clear payer pathways that account for lifecycle benefits rather than unit price alone. Yet, where these barriers are addressed, scaffold technologies have the potential to change therapeutic paradigms for selected coronary and peripheral indications.

The pathway to success requires a disciplined alignment of device design with clinical indication, targeted evidence generation that responds to stakeholder concerns, and operational investments that secure reliable manufacturing and distribution. Organizations that integrate clinical leadership with agile supply chain strategies and clear reimbursement value propositions will be best positioned to realize the clinical and commercial benefits of resorbable scaffolds. Ultimately, the devices that combine practicable procedural workflows, demonstrable patient benefits, and sustainable economics will determine the technology's long-term role in vascular intervention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Resorbable Vascular Scaffold Market, by Indication

  • 8.1. Coronary Artery Disease
    • 8.1.1. Acute Coronary Syndrome
    • 8.1.2. Stable Angina
  • 8.2. Peripheral Arterial Disease
    • 8.2.1. Claudication
    • 8.2.2. Critical Limb Ischemia

9. Resorbable Vascular Scaffold Market, by Material

  • 9.1. Magnesium
  • 9.2. Polylactic Acid

10. Resorbable Vascular Scaffold Market, by Scaffold Diameter

  • 10.1. Less Than 3 Millimeter
  • 10.2. Three Millimeter And Above

11. Resorbable Vascular Scaffold Market, by Scaffold Length

  • 11.1. Eighteen To Twenty Eight Millimeter
  • 11.2. Greater Than Twenty Eight Millimeter
  • 11.3. Less Than Eighteen Millimeter

12. Resorbable Vascular Scaffold Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Centers
  • 12.3. Hospitals

13. Resorbable Vascular Scaffold Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Resorbable Vascular Scaffold Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Resorbable Vascular Scaffold Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Resorbable Vascular Scaffold Market

17. China Resorbable Vascular Scaffold Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Biotronik SE & Co. KG
  • 18.7. Boston Scientific Corporation
  • 18.8. Cardionovum GmbH
  • 18.9. Elixir Medical Corporation
  • 18.10. Meril Life Sciences Private Limited
  • 18.11. MicroPort Scientific Corporation
  • 18.12. Shandong Huaan Biotechnology Co., Ltd.
  • 18.13. Terumo Corporation
  • 18.14. Xeltis AG
  • 18.15. Zorion Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 160. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 162. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 168. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 170. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)